Oncología médica
Especialidad
Centre François Baclesse
Esch-sur-Alzette, LuxemburgoPublikationen in Zusammenarbeit mit Forschern von Centre François Baclesse (5)
2023
2015
-
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
Scientific Reports, Vol. 5
2012
2007
-
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Lancet, Vol. 369, Núm. 9561, pp. 559-570
2004
-
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
New England Journal of Medicine, Vol. 350, Núm. 11, pp. 1081-1092